AstraZeneca PLC (AZN)

NYQ – Real Time Price. Currency in USD

157.99

-0.76 (-0.48%)

Market open: Aug 12, 2026, 10:48 AM EDT

158.80

+0.05 (0.03%)

Previous after-hours: Aug 11, 2026, 7:52 PM EDT

07.08.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

06.08.2026

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integration risk. The reports had the industry thinking about a kind of dealmaking it has avoided for more than a decade.

06.08.2026

Deal or No Deal, AstraZeneca Stock Is a Bargain

The logic of a pharma megamerger is questionable, but AstraZeneca's record isn't.

05.08.2026

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential ‌deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers.

04.08.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

04.08.2026

Brokers split on AstraZeneca merger talk as shares recover some ground

Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a Financial Times report over the weekend that the FTSE 100 drugmaker is in discussions over a merger with US rival Bristol Myers Squibb.

04.08.2026

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year collaboration agreement will advance the development and commercialization of two companion diagnostic programs, bringing SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.

Videos

No Data

There is no data to display

Press releases

07.08.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

04.08.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

04.08.2026

AstraZeneca PLC (AZN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AstraZeneca PLC (AZN)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Deal or No Deal, AstraZeneca Stock Is a Bargain

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Brokers split on AstraZeneca merger talk as shares recover some ground

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

Videos

No Data

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Deal or No Deal, AstraZeneca Stock Is a Bargain

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Brokers split on AstraZeneca merger talk as shares recover some ground

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

Videos

No Data

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

Search stocks

AstraZeneca PLC (AZN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AstraZeneca PLC (AZN)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Deal or No Deal, AstraZeneca Stock Is a Bargain

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Brokers split on AstraZeneca merger talk as shares recover some ground

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

Videos

No Data

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

Deal or No Deal, AstraZeneca Stock Is a Bargain

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Brokers split on AstraZeneca merger talk as shares recover some ground

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

Videos

No Data

Press releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies